Lupin and peers run into US FDA headwinds again

Ravi Ananthanarayanan • March 18, 2019 / 18:25 IST

Lupin’s shares fell after an FDA inspection led to its US unit being issued an adverse warning. Other pharma companies too have tripped on inspections, raising fears that compliance issues are very much alive for the industry

To read the full story,

Are you a PRO subscriber? Sign In

Ad free Experience

Seamless navigation, faster responses.
Expert Perspective

Explore 230+ exclusive editorials every month
+

Uncover Insights from World-Renowned Experts and Journalists
Actionable Insights

40+ weekly investment ideas + 3 to 4 daily technical calls
Virtual Events

Exclusive Live Webinars for Expert Trading & Investment Strategies!
Newsletters

Stay ahead with daily and weekly insights

Unlock exclusive discounts